“I’ve been attacked before, but I’ve never seen one as egregious as this one in terms of ‘Andy Kim’s trying to cut Medicare,’” Kim said. That provision to control drug prices became a focal point of the $1.75 trillion spending package Democrats are trying to move through Washington. Pharmaceutical industry lobbyists defended their effort, alleging the Democrats’ proposal would stifle research. The drug pricing provision agreed to by House Democrats this week does not go as far as many Democrats like Kim had hoped. “What we’re trying to do is defying one of the most powerful special-interest lobby groups in Washington, D.C.,” Kim said.
